Superagonistic anti-CD28 antibodies

A pharmaceutical composition comprising a binding molecule that specifically binds a human CD28 molecule, wherein the binding molecule is encoded by a nucleic acid sequence comprising:

• (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein
• (i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS:
• 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS:
• 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1);
• and
• (ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS:
• 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28(CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS:
• 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1);
• and
• (b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody;
• and a pharmaceutically acceptable molecule.